NEW YORK (GenomeWeb News) – Dyax is granting GE Healthcare rights to develop and commercialize c-Met imaging peptides for potential use in patient selection under a deal announced today.
Under the terms of the deal, GE will pay biopharmaceutical firm Dyax upfront, milestone, and royalty payments. Further terms were not disclosed.
GE said it plans to explore with academic and pharmaceutical collaborators use of the peptides for diagnostic applications as well as for selection of patients for cancer research. The license being granted also includes application of the peptides in positron emission tomography, single proton emission computed tomography, and optical imaging.
"As in vivo imaging technologies become increasingly important in oncology drug development, our vision is that we will be able to rapidly develop new targeted molecular diagnostics — not just for our own clinical portfolio, but as companion diagnostic offerings for our strategic biopharmaceutical partnerships," Marivi Mendizabal, head of research, GE Healthcare Medical Diagnostics, said in a statement.